Lyell Immunopharma (NASDAQ:LYEL) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of Lyell Immunopharma (NASDAQ:LYEL) from a hold rating to a sell rating in a report published on Saturday morning,Wall Street Zen reports.

LYEL has been the subject of a number of other research reports. Royal Bank Of Canada set a $34.00 target price on Lyell Immunopharma in a report on Friday, August 14th. Zacks Research raised shares of Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a research report on Friday, August 14th. B. Riley Financial assumed coverage on shares of Lyell Immunopharma in a report on Wednesday, July 22nd. They set a “buy” rating and a $44.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of Lyell Immunopharma in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $40.86.

Lyell Immunopharma Trading Down 2.0%

Lyell Immunopharma stock opened at $11.96 on Friday. The firm has a 50 day simple moving average of $14.04 and a 200 day simple moving average of $17.27. Lyell Immunopharma has a 1-year low of $11.47 and a 1-year high of $45.00. The firm has a market capitalization of $293.02 million, a price-to-earnings ratio of -0.93 and a beta of -0.04.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.94) by $0.02. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%.The firm had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.00 million. On average, equities research analysts forecast that Lyell Immunopharma will post -7.2 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC boosted its holdings in Lyell Immunopharma by 194.8% during the 1st quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock valued at $2,335,000 after acquiring an additional 76,921 shares during the period. MWG Caph Ltd purchased a new position in Lyell Immunopharma in the 4th quarter worth approximately $31,030,000. venBio Partners LLC bought a new stake in Lyell Immunopharma in the second quarter valued at approximately $4,744,643. Opaleye Management Inc. boosted its stake in shares of Lyell Immunopharma by 334.9% during the second quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock valued at $4,834,000 after purchasing an additional 264,928 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Lyell Immunopharma during the first quarter valued at approximately $959,000. 66.05% of the stock is currently owned by institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.